The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis

Table 3

Summary of meta-analysis results.

Outcomes	No. of studies	HR/RR 95% CI	value	value^c	Study heterogeneity
					Chi^2 (χ^2)	df	I^2, %	value^c
Pre-DNA
OS	11	3.45^a	3.23	0.001	42.20	10	76	<0.00001
PFS	5	2.37^a	3.94	<0.0001	2.45	4	0	0.65
CR	3	1.45^b	3.77	0.0002	0.37	2	0	0.83
ORR	5	1.57^b	4.13	<0.0001	6.79	4	41	0.15
Post-DNA
OS	5	2.30^a	2.60	0.009	0.97	4	0	0.91
PFS	4	2.35^a	3.14	0.002	2.14	3	0	0.54

No.: number; HR: hazard ratio; RR: relative risk; CI: confidence interval; pre-DNA: pretreatment EBV-DNA; post-DNA: posttreatment EBV-DNA; OS: overall survival; PFS: progression-free survival; CR: complete response; ORR: overall response rate. ^aHazard ratios. ^bRisk ratios. ^cStatistically significant results are shown in bold.